<SEC-DOCUMENT>0001564590-21-020624.txt : 20210427
<SEC-HEADER>0001564590-21-020624.hdr.sgml : 20210427
<ACCEPTANCE-DATETIME>20210426194045
ACCESSION NUMBER:		0001564590-21-020624
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210426
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210427
DATE AS OF CHANGE:		20210426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		21855501

	BUSINESS ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eldn-8k_20210426.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eldn-8k_20210426.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d)<br />of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">April 26, 2021<br /><font style="font-size:10pt;font-weight:normal;">Date of Report <br />(Date of earliest event reported)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eledon Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:3pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">__________________________________________________________________________________________</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:32.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:31.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:31.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;of incorporation)</p></td>
<td valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-36620</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20-1000967</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19900 MacArthur Blvd., Suite 550</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Irvine, California 92612</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including Zip Code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(949) 238-8090</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<font style="font-family:Times New Roman;">&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:99.95%;">
<tr>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.4pt;width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.4pt;width:1%; border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.4pt;width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.4pt;width:1%; border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.4pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.4pt;padding-Bottom:0.25pt;width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.001 par value</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.4pt;padding-Bottom:0.25pt;width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ELDN</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.4pt;padding-Bottom:0.25pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Capital Market</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company <font style="color:#000000;font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="color:#000000;font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:98.99%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:15.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="s33131E19F9425C91FD2639AE9BB64548"></a><font style="text-decoration:underline;">Item 8.01</font><font style="font-weight:normal;"> </font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:84.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Other Events&#160;&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66207022"></a><a name="_Hlk66207177"></a>On April 26, 2021, Eledon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing an update on the Company&#8217;s development strategy for AT-1501 in renal transplantation. A copy of the press release is attached hereto as Exhibit 99.1. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Item 9.01</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;margin-left:36pt;"></font><font style="text-decoration:underline;">Financial Statements and Exhibits</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:14.48%;"></td>
<td style="width:85.52%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eldn-ex991_14.htm"><font style="text-decoration:underline;">Press Release, dated April 26, 2021</font></a></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*<font style="margin-left:36pt;"></font>*<font style="margin-left:36pt;"></font>*</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:139.85%;">
<tr>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:55.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:23.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:12.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:8.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="9" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:40.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eledon Pharmaceuticals, Inc.</p></td>
<td colspan="4" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:40.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 26, 2021</p></td>
<td colspan="3" valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:-48pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ David-Alexandre C. Gros&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:40.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:-48pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: David-Alexandre C. Gros</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:40.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:-48pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Executive Officer</p></td>
<td colspan="2" valign="middle"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="5" valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom"  style="padding-left:1.75pt;padding-Right:1.75pt;padding-Top:1.75pt;padding-Bottom:1.75pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eldn-ex991_14.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eldn-ex991_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdmjrqsqojc0000001.jpg" title="" alt="" style="width:257px;height:64px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Eledon Pharmaceuticals Announces Update on Development Strategy for </p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">AT-1501 in Renal Transplantation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">IRVINE, Calif., April 26, 2021<font style="font-weight:normal;"> &#8211; Eledon Pharmaceuticals, Inc. (&#8220;Eledon&#8221;) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced an updated development strategy for AT-1501 in renal transplantation.  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of ongoing discussions with the U.S. Food and Drug Administration&#160;(FDA) regarding the AT-1501 renal transplant program, the FDA requested that Eledon provide AT-1501 specific, renal transplant data in non-human primates prior to initiating a Phase 2 trial in renal transplantation in the United States. As a result, Eledon plans to initiate an evaluation of AT-1501 in a standard non-human primate model of renal transplantation which is expected to be completed by late 2022.&nbsp;&nbsp;In parallel, the company will continue to explore potentially conducting a renal transplantation clinical trial outside the United States.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_Hlk68697855"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA request and this shift in development strategy is specific to the previously planned Phase 2 trial in renal transplantation; the company&#8217;s other ongoing development programs are continuing in both the United States and Canada as previously communicated. No significant drug-related safety signals with AT-1501 have been identified to date, and this change in development strategy is not due to any specific event in or data from the company&#8217;s ongoing trials of AT-1501. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We will continue to work collaboratively with the FDA to generate additional renal transplantation preclinical data prior to conducting a Phase 2 trial in renal transplantation with AT-1501 in the United States,&#8221; stated Steve Perrin, Ph.D., President and Chief Scientific Officer. &#8220;We continue to believe that AT-1501 is a differentiated anti-CD40L antibody that can be an important treatment option for patients undergoing renal transplantation. We remain committed to designing and executing a robust clinical development program to show that AT-1501 has the potential to prevent rejection and prolong allograft survival. We look forward to providing further updates on our revised renal transplantation program in the coming months.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Eledon Pharmaceuticals and AT-1501</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company&#8217;s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company&#8217;s website at </font><font style="text-decoration:underline;">www.eledon.com</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Follow Eledon Pharmaceuticals on social media: <font style="text-decoration:underline;">@Eledon_Pharma and LinkedIn</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company&#8217;s future expectations, plans and prospects, including statements about development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company&#8217;s capital resources and ability to finance planned clinical trials, as well as other statements containing the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;targets,&#8221; &#8220;looks forward,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company&#8217;s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company&#8217;s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Investor Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corey Davis, Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LifeSci Advisors, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">cdavis@lifesciadvisors.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212.915.2577</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Eledon Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gdmjrqsqojc0000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdmjrqsqojc0000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "4 DX# 2(  A$! Q$!_\0
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MP3IETNDC4WCVVS2B)&/5S@DX]ACKZ_CBG7I?Q!1(O#=K'&BHB7**JJ,  (^
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MO8^C>_Y^H\Q='BD:.1&1T)5E88((Z@BO?I5:>*IM/YH^'Q&&Q&65U)/T??\
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M\7&.)S/$=V_N2_R&>$O!_P!L":CJ49%N?FBA/63_ &C_ +/IZ_3KZ,JJBA5
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M-):>&[Q47'-SMM\_3S"N1]*^C?AQ\*-)\#V4-U<1Q7NO$$RWA&1$2,%8@>@
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MO'_HB2OK^@#X@_X03QA_T*FN?^"Z;_XFC_A!/&'_ $*FN?\ @NF_^)K[?HH
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MTR,5)U2V7(]#(H/Z&OMV@#Y@_:._Y*'I_P#V"H__ $;+7C]>P?M'?\E#T_\
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M-;W(;Y,\*P&=WY#'XCTK3'8.,HNK'1K<Y\FS6=.<</4UB]%Y?\#\CO\ 7/\
MD7]2_P"O67_T UXG7MFN?\B_J7_7K+_Z :\3I97\$O4KB3^+#T/3?AU_R+]Q
M_P!?3?\ H"5H^,?^13OOHO\ Z&M9WPZ_Y%^X_P"OIO\ T!*T?&/_ "*=]]%_
M]#6N.I_OGS1ZU#_D4_\ ;C_)GD->F_#K_D7[C_KZ;_T!*\RKTWX=?\B_<?\
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M:>!R22,<$9->BT %>=?%WX=_\)SX>6;3XH_[;LLM;,S;?-7^*(GISU!/0CJ
M2:]%HH ^!)X)K6XEM[B*2&>)RDD<BE61@<$$'D$'M6MX<\6:[X2O3=:)J,UH
M[X\Q%.4DP"!N0Y5L9.,CC/&*^K/'7PJ\/^.5:XG1K+5,?+?6ZC<QVX D'1U'
M'H?E # 5X7K?P"\::;<E=/AMM5MR6VR03+&P4'C<LA&"1V4M]: .BT[]I;48
MK<KJ?ANUN9MW#VURT"X]-K!SGWS5/6_VCM?O(VCT?2;/30T94R2N;B16_O*<
M*HQZ%37G+^ /&,<K1MX5UHLIP2MC(P_,#!^M=/I'P*\<ZG,HGL(--A9-WG7=
MPN.W&U-S _4#IUH XG4-3UGQ5K0N+ZXNM2U&Y<(@.79BS<(BCH,GA5&.< 5K
M^.O!LW@B\TG3[MR;ZXTY+JZ7<"L<C22#8"/154'D\Y(.,5]+^ ?A-H7@4)=#
M_B8:P-P-_*FTJ#QA$R0G'&>2<MS@X&%\7_A1?>.+RUUC1[J);^"#[/);W#;4
MDC!9@5(!PV6(P>"".1CD ^6Z^_Z^8_"W[/WB.YU>VE\0BUL].CF4W$7G;Y)4
M')5=G STR6!&<X.,'Z<H *\*^-/PGEU*9_%'ARS>2[;F^M(ADR^DB+_>[$#K
MP<9SGW6B@#X KMO"'Q6\5>"[=;/3[J*XL%W%;2[3?&I/=2"&7GG (&23CFO?
M_&_P5\.^+YY;^V9M)U21BSSP(&CE8D$L\>1D_>Y!4Y;)W5XSJ_P#\<:?,%L[
M:TU.,Y.^VN%7:!TR)-O)]L_6@#KH_P!IEQ$@E\)JT@4;F74-H)[D#RS@>V36
M#X@_:'\3ZB'BT>TM-)B;&'QY\R^OS, N#_N9'K7"3?#[QE;S/$_A762R'!,=
ME(Z_@R@@_@:UM-^#OCW4TBDCT"6"*1@-UU*D)0>I5B&P/IF@#B;BXGN[F6YN
M9I)IY6+R2R,69V/)))Y)/K79?#GX<ZCX\U= $EATB&0"[O , #J40G@N1CUQ
MD$^_J'A;]G&&">.X\4ZHMP%.39V.51L$8W2-AB",@@*IYX;BO;].TVRTC3X;
M#3K6*UM(1B.&)0JKSD\>Y))/<DF@ TW3;/1],MM.T^!8+2VC$<42YPJCW/)/
MN>3U-6J** /F#]H[_DH>G_\ 8*C_ /1LM>/U]4_%_P"%5WXZFL=4T>>WCU&V
MC,$J7#,JRQY++@C."&+=N=W)&.?-/#G[/OB:]U.+^W3!IVGJX\XI.KRNO<(%
MR,]LL>,YP<8H ^H:*** "BBB@#X@\=_\E#\3?]A6Z_\ 1K5S]>Z_$+X%Z_>^
M)]0UCP_)!>6]].UPT$LH26-W)9QR I7)XYS@XP<9-WP!\ 6@N9KOQK':SP/#
MMALH9GW*Y()9F4@# &, L#N/3'(![VZ+(C(ZAD8896&01Z&O-_%/@YK 27^G
M*7M1\TD74Q#U'JO\J]*HK>AB)T97B<6-P-+&4^6>_1]CP2NN\+^,7TW99:@S
M26?1'ZM%_BOMV[>E6/%WA#[+YFI:9'_H_P!Z:!1_J_\ :4?W?4=OITXFO>3I
M8NEY?D?$M8G+,1V:^YK_ "/>4=)8UDC=71P&5E.00>A!IU>6>%/%;Z/(+.\9
MGL'/!ZF$GN/;U'XCN#ZC'(DL:R1NKHX#*RG((/<&O"Q&&E0E9[=S[3 8^GC*
M?-'1K==O^ 4M<_Y%_4O^O67_ - ->)U[9KG_ "+^I?\ 7K+_ .@&O$Z]+*_@
MEZGS_$G\6'H>F_#K_D7[C_KZ;_T!*T?&/_(IWWT7_P!#6L[X=?\ (OW'_7TW
M_H"5H^,?^13OOHO_ *&M<=3_ 'SYH]:A_P BG_MQ_DSR&O3?AU_R+]Q_U]-_
MZ E>95Z;\.O^1?N/^OIO_0$KTLQ_@?,^?R#_ 'Q>C.NHHHKY\^Y"BBB@ HHH
MH **** "BBB@ HHHH ***:[I&NYW55]6.!0 ZBH?MEM_S\P_]]BI5964,I!!
MZ$&@!:**R;;Q-H]WXDO?#T%ZK:M91K+/;;&!5&"D')&#PZ]"<9% &M1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !115.75M-AU.'3)=0M(]0G7?%:O,HED7GE4SDCY6Y ['TH
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M444 %%%% !7DOQNMX[^X\%Z=<AGL[K64CFBW$!U)"GI[,1GJ,FO6J\J^,/\
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MF\!ZAXCO_#K+XJL/LNJ6L[VSN!A;D+C$P&, -D].#@D8!  !T]%%% !1110
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8:7:I:V<"[8XDZ#\3R23R2>2>M%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
